For live cell therapies, the manufacturing process fundamentally shapes the biological product. Teams often rush to scale production, focusing on yield and cost. Instead, they should first fully understand how the process impacts cell potency and function to avoid effectively scaling the wrong biology.
Unlike immune cells engineered to kill tumors (e.g., CAR-T), Mesenchymal Stem Cells (MSCs) solve a different problem. Their primary role is to leverage natural trafficking ability to reach the tumor microenvironment and deliver therapeutic payloads, rather than acting as immune effectors themselves.
A dual-payload strategy attacks cancer on two fronts. One payload induces localized tumor damage via chemotherapy. The second simultaneously supplies a key immune signal (interferon beta) that aggressive tumors suppress, converting the damage into a robust, recognizable anti-tumor immune response.
Relying on a single safety mechanism is risky for potent therapies. A more robust approach stacks multiple independent layers of control: localized administration, requiring a separate prodrug for activation, and exploiting the inherent vulnerability of rapidly dividing cancer cells.
Engineered Mesenchymal Stem Cells (MSCs) can be designed to be sensitive to the very drug they produce from a prodrug. This creates an elegant self-regulating mechanism where the therapeutic cells are eliminated as they perform their function, preventing long-term persistence and enhancing the safety profile.